Drug Trial Radar · NCT05449444
Masitinib for the Treatment of Severe Mast Cell Activation Syndrome
Last checked: Nov 20, 2026Latest source record: Feb 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
72
Planned (sponsor's estimate)
Start
Jul 1, 2022
Primary completion
Dec 31, 2024
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- AB ScienceIndustry
- Sponsor type
- Industry
- First posted
- Jul 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of two dosing schemes of oral masitinib versus matching placebo in the treatment of patients suffering from severe MCAS with handicap unresponsive to optimal symptomatic treatment.
Conditions
- Mast Cell Activation Syndrome
Interventions
Masitinib 4.5 mg/kg/dayDrug
Masitinib 4.5 mg/kg/day
PlaceboDrug
Matching placebo
Best supportive careOther
Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, sodium cromoglicate, antidepressants, antileukotrienes, proton pump inhibitors, and corticosteroids.
Masitinib 6.0 mg/kg/dayDrug
Masitinib 6.0 mg/kg/day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Confirmed response at 50%Time frame: 24 weeks
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
St Charles Clinical Research
Weldon Spring, Missouri · Recruiting
Centre Hospitalier Universitaire Amiens-Picardie
Amiens, France · Recruiting
Necker-Enfants Malades Hospital, Centre de référence des Mastocytoses (CEREMAST)
Paris, France · Recruiting
CHU Toulouse
Toulouse, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.